The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy

Henry, Ann; Rodda, S.; Mason, M. K.; Musunuru, Hima Bindu; Al-Qaisieh, B.; Bownes, Peter; Smith, Jonathan; Franks, K.; Carey, B.; Bottomley, David

doi:10.1016/j.clon.2015.03.004

Cited by 8 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was based on several published series that have shown a relationship between this value and bDFS. 8,9 The ability of our series to identify such a relationship was impaired by our sample size and number of events. Other single centre series have also failed to show an effect.…”

Section: Discussionmentioning

confidence: 97%

“…To evaluate the effect of D90 dose on bDFS we selected a D90 cut‐off value of 140 Gy. This was based on several published series that have shown a relationship between this value and bDFS . The ability of our series to identify such a relationship was impaired by our sample size and number of events.…”

Section: Discussionmentioning

confidence: 99%

“…The relationship between dose delivered to the prostate and biochemical control has been well described with varying results. Optimal biochemical control has thus far not been consistently attributed to a specific D90 dose . There are few published reports on long‐term morbidity outcomes …”

Section: Introductionmentioning

confidence: 99%

“…Optimal biochemical control has thus far not been consistently attributed to a specific D90 dose. [8][9][10] There are few published reports on long-term morbidity outcomes. 11,12 The Sir Charles Gairdner Hospital was the first Australian centre to deliver Iodine-125 permanent interstitial prostate implants.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Ten‐year outcomes using low dose rate brachytherapy for localised prostate cancer: An update to the first Australian experience

et al. 2016

View full text Add to dashboard Cite

Introduction: To report long-term prostate-specific antigen (PSA) and toxicity outcomes for patients with localised prostate cancer treated with Iodine-125 permanent implantation at a single Australian centre. Methods: Between September 1994 and November 2007, 207 patients at Sir Charles Gairdner Hospital with localised prostate cancer were consecutively treated with Iodine-125 permanent interstitial implantation. Posttherapy assessment was performed three times a month and included clinical review and biochemical (PSA) evaluation. PSA progression was evaluated using the Phoenix (nadir + 2.0) definition. Treatment-related morbidity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 guidelines. The rate of biochemical failure was calculated by Kaplan-Meier plots. Univariate and multivariate analyses were performed to evaluate outcomes by pre-treatment clinical prognostic factors and radiation dosimetry. Results: Median follow-up was 7.8 years. The 10-year biochemical disease-free survival (bDFS) for the entire cohort was 89%. Ten-year bDFS estimates by pre-treatment risk group were 96% for low-risk, 83% for intermediate-risk and 50% for high-risk disease. On multivariate analysis, pre-treatment PSA was an independent predictor of bDFS. D90 dose did not show a statistically significant effect on bDFS. The peak incidences of late grade 3 or higher urinary and rectal toxicities were 10.7% and 1.1% respectively. Conclusion: Excellent long-term biochemical control was demonstrated with Iodine-125 permanent interstitial implantation in appropriately selected patients with prostate cancer. The results of our single centre experience are comparable with those of other single institutions.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ten‐year outcomes using low dose rate brachytherapy for localised prostate cancer: An update to the first Australian experience

et al. 2016

View full text Add to dashboard Cite

show abstract

“…International guidelines have recommended dosimetry for permanent 125 I prostate implants 1 month after the implantation procedure, when prostate swelling from edema has resolved (1)(2)(3)(4). The dosimetry at day 30 correlates with the clinical treatment outcome (1,(5)(6)(7). However, it is difficult to predict the day 30 dosimetry during the implantation procedure (4,(8)(9)(10)(11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Edema and Seed Displacements Affect Intraoperative Permanent Prostate Brachytherapy Dosimetry

Westendorp

Nuver

Hoekstra

et al. 2016

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

show abstract

Cone-beam CT-based adaptive planning improves permanent prostate brachytherapy dosimetry: An analysis of 1266 patients

et al. 2017

View full text Add to dashboard Cite

Purpose: To evaluate adaptive planning for permanent prostate brachytherapy and to identify the prostate regions that needed adaptation. Methods and materials: After the implantation of stranded seeds, using real-time intraoperative planning, a transrectal ultrasound (TRUS)-scan was obtained and contoured. The positions of seeds were determined on a C-arm cone-beam computed tomography (CBCT)-scan. The CBCT-scan was registered to the TRUS-scan using fiducial gold markers. If dose coverage on the combined imagedataset was inadequate, an intraoperative adaptation was performed by placing remedial seeds. CBCT-based intraoperative dosimetry was analyzed for the prostate (D 90 , V 100 , and V 150 ) and the urethra (D 30 ). The effects of the adaptive dosimetry procedure for Day 30 were separately assessed. Results: We analyzed 1266 patients. In 17.4% of the procedures, an adaptation was performed. Without the dose contribution of the adaptation Day 30 V 100 would be < 95% for half of this group. On Day 0, the increase due to the adaptation was 11.8 AE 7.2% (1SD) for D 90 and 9.0 AE 6.4% for V 100 . On Day 30, we observed an increase in D 90 of 12.3 AE 6.0% and in V 100 of 4.2 AE 4.3%. For the total group, a D 90 of 119.6 AE 9.1% and V 100 of 97.7 AE 2.5% was achieved. Most remedial seeds were placed anteriorly near the base of the prostate. Conclusion: CBCT-based adaptive planning enables identification of implants needing adaptation and improves prostate dose coverage. Adaptations were predominantly performed near the anterior base of the prostate.

show abstract

The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy

Cited by 8 publications

References 15 publications

Ten‐year outcomes using low dose rate brachytherapy for localised prostate cancer: An update to the first Australian experience

Ten‐year outcomes using low dose rate brachytherapy for localised prostate cancer: An update to the first Australian experience

Edema and Seed Displacements Affect Intraoperative Permanent Prostate Brachytherapy Dosimetry

Cone-beam CT-based adaptive planning improves permanent prostate brachytherapy dosimetry: An analysis of 1266 patients

Contact Info

Product

Resources

About